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Abstract. 
 
The 
 
H-rev107
 
 gene is a new class II tumor 
suppressor, as defined by its reversible downregulation 
and growth-inhibiting capacity in 
 
HRAS
 
 transformed 
cell lines. Overexpression of the 
 
H-rev107
 
 cDNA in 
 
HRAS
 
-transformed ANR4 hepatoma cells or in FE-8 
fibroblasts resulted in 75% reduction of colony forma-
tion. Cell populations of 
 
H-rev107
 
 transfectants showed 
an attenuated tumor formation in nude mice. Cells ex-
planted from tumors or maintained in cell culture for 
an extended period of time no longer exhibited detect-
able levels of the H-rev107 protein, suggesting strong 
selection against 
 
H-rev107
 
 expression in vitro and in 
vivo. Expression of the truncated form of H-rev107 
lacking the COOH-terminal membrane associated do-
main of 25 amino acids, had a weaker inhibitory effect 
on proliferation in vitro and was unable to attenuate tu-
mor growth in nude mice. The 
 
H-rev107
 
 mRNA is ex-
pressed in most adult rat tissues, and immunohis-
tochemical analysis showed expression of the protein in 
differentiated epithelial cells of stomach, of colon and 
small intestine, in kidney, bladder, esophagus, and in 
tracheal and bronchial epithelium. 
 
H-rev107
 
 gene tran-
scription is downregulated in rat cell lines derived from 
liver, kidney, and pancreatic tumors and also in experi-
mental mammary tumors expressing a 
 
RAS
 
 transgene. 
In colon carcinoma cell lines only minute amounts of 
protein were detectable. Thus, downregulation of 
 
H-rev107
 
 expression may occur at the level of mRNA 
or protein.
 
R
 
as
 
 gene mutations contribute to a large proportion
of human cancers. Point mutations activating one
of the three 
 
RAS
 
 genes are detected in 50% of co-
lon carcinomas and adenomas 
 
.
 
1 cm in size (Vogelstein et
al., 1988), in 
 
z
 
90% of pancreatic tumors, in 30% of lung
carcinomas and myeloid leukemias, and in 50% of thyroid
tumors (for review see Bos, 1989). In most of these tu-
mors, 
 
RAS
 
 mutations are present in early stages of the
neoplastic disease, suggesting a role in the initiation of ma-
lignant transformation. The normal RAS protein is acti-
vated by GDP/GTP nucleotide exchange factors in re-
sponse to the binding of different ligands to their cognate
receptors. Thereby, RAS couples extracellular stimuli
with the activation of genes controlling proliferation, dif-
ferentiation, and growth arrest (for review see Marshall,
1995). In its active, GTP-bound form, RAS targets the
protein kinase, Raf, to the cell membrane, where Raf ini-
tiates a protein kinase cascade resulting in transcription
factor activation (Leevers et al., 1994; Stokoe et al., 1994).
RAS is inactivated by hydrolysis of GTP to GDP. Muta-
tions affecting amino acids 12, 13, or 61 within the RAS
protein not only lead to a reduction of its intrinsic GTPase
activity but also to its resistance to the action of various
GTPase activating proteins that highly enhance the GTP
to GDP conversion of normal RAS. These RAS mutants
are trapped in the active GTP-bound state and constitu-
tively stimulate downstream kinases. Similar effects can
also be achieved by mutations in one of these GAPs, such
as 
 
NF1.
 
 Mutations within the coding sequence of the 
 
NF-1
 
gene disrupt this activity and are thought to contribute to
neoplasia associated with neurofibromatosis type I (Caw-
thon et al., 1990; Viskochil et al., 1990). Recently, consider-
able progress has been made in the elucidation of the
pathways activated by GTP-bound RAS (for review see
Marshall, 1995). Several different protein kinases, includ-
ing Raf-1, PI-3-kinase, PKC-
 
z
 
, and MEK kinase, have
been identified as downstream effectors of RAS. All of
them stimulate distinct protein kinase cascades, resulting
in mitogenic stimulation and morphological alterations
(Marshall, 1995). These effects are thought to be mediated
via distinct transcriptional targets of the protein kinase
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cascades. Two well known genes activated in response to
oncogenic RAS-activation are the immediate–early genes
 
Fos
 
 and 
 
Jun
 
 encoding the heterodimeric AP-1 transcription
factor. The AP-1 complex stimulates the transcription of
genes encoding tissue remodeling enzymes relevant for
the metastatic phenotype such as type IV collagenase and
the metalloprotease stromelysin (Scher et al., 1983; Muller
et al., 1988; Chauhan et al., 1991). Gene products involved
in cellular metabolism, such as glucose transporters or orni-
thine-decarboxylase, are also found at increased levels in
RAS-transformed cells and may contribute to the in-
creased division rate of tumor cells (for review see Aoyama
and Klemenz, 1993).
Oncogenic mutations of Ras also lead to the transcrip-
tional downregulation of critical genes. They encode the
F-actin capping proteins such as gelsolin (Müllauer et al.,
1993), matrix modifying enzymes such as rrg-1 (Contente
et al., 1990), and the F-actin bundling proteins tropomyo-
sin (Prasad et al., 1993) and vinculin (Fernandez et al.,
1992). In addition, the expression of protein kinase C fam-
ily isoforms is abrogated after activation of oncogenic
 
HRAS
 
 (Geiges et al., 1995), and some downregulated
genes have been described with as yet unknown function,
e.g., the 322 gene (Lin et al., 1995). Several of those genes
were shown to be reexpressed in the revertant cell lines
derived from 
 
HRAS
 
-transformed fibroblasts (for review
see Schäfer, 1994). Therefore, the reversible functional loss
of these gene activities may be causally involved in the pro-
cess of neoplastic transformation. These observations sug-
gest a specific interference of the proteins encoded by down-
regulated genes with the oncogenic signaling pathways.
We have established a series of closely related immortal,
nontumorigenic 208F rat fibroblasts, 
 
HRAS
 
-transformed
FE-8 cells, and phenotypic revertants for the identification
of transcriptional targets suppressed by an activated
 
HRAS
 
 gene (Schäfer et al., 1988). Using cDNA subtrac-
tion and differential hybridization, we analyzed the ex-
pression pattern of known transformation-sensitive genes
in these cells (Oberhuber et al., 1995) and isolated new se-
quences, designated 
 
H-rev
 
 genes, associated with the nor-
mal and the revertant phenotype (Hajnal et al., 1993, 1994;
Kiess et al., 1995). One of these genes, 
 
H-rev107
 
, a novel,
16-kD protein without known sequence homologies, is ex-
pressed in immortal rat fibroblasts, downregulated after
 
HRAS
 
-transformation, reexpressed in the revertant clone
F9, and also highly expressed in two independent 
 
RAS
 
-
resistant fibroblast lines (Hajnal et al., 1994). This result
suggested that the 
 
H-rev107
 
 gene was directly involved in
the resistance toward 
 
HRAS
 
-mediated transformation. In
this study, we demonstrate the growth-inhibitory effects of
 
H-rev107
 
 overexpression on 
 
HRAS
 
-transformed cells in
vitro and in vivo. Furthermore, we show the ubiquitous ex-
pression of 
 
H-rev107
 
 in normal tissues and its downregula-
tion in rat tumor cell lines and in experimental tumors.
 
Material and Methods
 
Cell Lines and Cell Culture
 
The 
 
EJ-ras
 
 transformed rat hepatoma cell line ANR4, the rat colon carci-
noma cell lines DHD and WB2054, the rat pancreatic tumor cell lines
CRI-D2 and CRI-D11, and the 
 
Ki-RAS
 
 transformed rat kidney cell line
KNRK were obtained from the European Collection of Animal Cell Cul-
tures (Porton Down, UK). The immortal rat pancreatic cell line AR4-IP
and the transformed rat pancreatic cell line AR4-2J were obtained from
Dr. O. Hagenbüchle (Lausanne, Switzerland). The immortal rat kidney
cell lines, NRK 49F and NRK 52E, were obtained from the American Type
Culture Collection (Rockville, MD). 208F (Quade, 1979) and REF52 (Franza
et al., 1986) are immortalized, nontumorigenic rat fibroblast cell lines. The
FE-8 cell line is an 
 
HRAS
 
-transformed derivative of 208F (Griegel et al.,
1986). Clone F9 is a phenotypic revertant cell line derived from FE-8
(Schäfer et al., 1988). Cells were grown in DME medium supplemented
with 10% fetal calf serum, penicillin (100 U/ml), and streptomycin (100
 
m
 
g/ml), standard medium. ANR4 cells were grown in Williams E medium
supplemented with 10% fetal calf serum, penicillin (100 U/ml), and strep-
tomycin (100 
 
m
 
g/ml). DHD cells were grown in DME/Hams F10 medium
(1:1); AR4-2J, AR4-IP, and WB2054 cells were grown in RPMI medium
supplemented with the same additives as above.
 
Northern Blot Analysis
 
Total cellular RNA was isolated as described (Chomczynski and Sacchi,
1987). 10 
 
m
 
g of RNA was denatured using glyoxal and separated in 1%
agarose gels (McMaster and Carmichael, 1977), and transferred to nylon
membranes (Genscreen plus, New England Nuclear, Boston, MA). North-
ern blots were hybridized with a 523-bp 
 
H-rev107
 
 cDNA fragment encod-
ing the 5
 
9
 
 untranslated sequence and part of the coding sequence as a
probe. Fragments were 
 
32
 
P labeled by random priming (Feinberg and Vo-
gelstein, 1983), and hybridization was carried out either in 50% forma-
mide, 10% dextran sulfate, 1 M sodium chloride, 5X Denhardt’s solution,
and 100 
 
m
 
g/ml denatured salmon sperm DNA at 42
 
8
 
C, or in the Quickhyb
solution from Stratagene (La Jolla, CA) at 65
 
8
 
C.
 
H-rev107 Expression Plasmids
 
H-rev107
 
 cDNA was cloned into expression vectors in which transcription
of the inserted DNA is driven by the cytomegalovirus promoter. Plasmids
pCMVTK107
 
1
 
 and pCMVTK107
 
2
 
 encode 
 
H-rev107
 
 mRNA in sense
and in antisense orientation, respectively (Hajnal et al., 1994). Plasmid
pCDNA-107
 
1
 
 was constructed by cloning the 900-bp BamHI insert, ob-
tained from the cDNA clone pBS107C, into the BamHI site of pCDNA3
(Invitrogen, San Diego, CA). This fragment contains the complete coding
region of 
 
H-rev107
 
, 33 bp of 5
 
9
 
 untranslated region, and 386 bp of 3
 
9
 
 un-
translated region. Plasmid pCDNA-107
 
2
 
 drives transcription of antisense
 
H-rev107
 
 mRNA. The pCDNA107 
 
D
 
C vector was constructed by PCR am-
plification of a 416-bp fragment obtained from pBS107C using the 
 
H-rev107
 
specific primers 5
 
9
 
 TTGAATTCAT GCCCATACCAGAACCCAAG 3
 
9
 
and 5
 
9
 
 GGGAGCTCTCGCCACCTTGACGATGTCT 3
 
9
 
, followed by
insertion of the PCR product into the EcoRI and XhoI sites of pCDNA3.
The termination codon is just downstream of the XhoI site in the vector.
This cDNA clone expresses only the first 135 amino acids of the H-rev107
protein. For the production of a tetracycline-inducible 
 
H-rev107
 
 (pUHD-
107), a 714-bp BamHI fragment from cDNA clone pBS107B (Hajnal et al.,
1994) was cloned into the BamHI site of the plasmid pUHD 10-3 (Gossen &
Bujard, 1992).
 
DNA Transfections and In Vivo Tumorigenicity Assays
 
Plasmid DNA was transfected into 208F, FE-8, and ANR4 cells by calcium–
phosphate precipitation, as described (Wigler et al., 1978). 5 
 
m
 
g of linear-
ized recombinant vector DNA, 1 
 
m
 
g of linearized plasmid pY3 carrying
the hygromycin B resistance gene, and 20 
 
m
 
g genomic carrier DNA were
used for transfection of 10
 
6
 
 recipient cells. 48 h after transfection, cells
were subjected to selection in standard medium containing 400 
 
m
 
g/ml hy-
gromycin B. When colonies had reached a size of 500–1,000 cells, the cells
were trypsinized and pooled. H-rev107 protein expression was analyzed
by immunofluorescence using the anti-H-rev107 antibody. To obtain FE-8
cells harboring a tetracyclin-inducible H-rev107, the cells were first trans-
fected with the plasmid pUHD172-1neo and stable clones selected as de-
scribed above. This plasmid expresses the modified tetracycline repressor
which was turned into an activator (Gossen et al., 1995). These clones
were analyzed by transient transfection using the plasmid pUHC13-3 con-
taining the luciferase-reporter gene under the control of a tet operator
(Gossen and Bujard, 1992). Clones showing a preferable ratio of induction
to background luciferase actvity were chosen for further transfection with
the pUHD-107 plasmid and clones selected by cotransfection with the
pY3 plasmid as described above. 48 h after induction of H-rev107 expres- 
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Transformation-suppressing Activity of H-rev107
 
937
 
sion using 2 
 
m
 
g/ml doxycyclin, protein expression was monitored either by
Western blot analysis or by immunofluorescence. For control cells (10-3-3),
the pUDH10-3 vector alone was used instead of pUHD-107. For tumori-
genicity assays, 10
 
6
 
 cells were injected subcutanously into either side of
ICR nu/nu mice. Tumor growth was controlled daily. After the indicated
time the animals were killed, tumors removed, and either frozen in liquid
nitrogen or explanted in tissue culture medium after digestion with
trypsin/EDTA. Tumor cells were incubated in standard medium contain-
ing 50 
 
m
 
g/ml gentamicin.
 
Preparation of Cell Extracts and Western Blot Analysis
 
For subcellular fractionation, adherent cells were washed twice in PBS, in-
cubated in hypotonic lysis buffer (10 mM Tris, 0.1 mM dithiothretiol, 1 mM
PMSF, 5 
 
m
 
g/ml aprotinin, 5 
 
m
 
g/ml leupeptin, 50 
 
m
 
g/ml TLCK, pH 8) for 5–10
min on ice, and lysed using a Dounce homogenizer. Nuclei were obtained
after centrifugation at 500 
 
g
 
 at 4
 
8
 
C for 10 min, washed twice in PBS, and
purified via centrifugation through a sucrose gradient (Blobel and Potter,
1966). The 500 
 
g
 
 supernatant was centrifuged at 100,000 
 
g
 
 at 4
 
8
 
C for 30
min to obtain the membrane fraction. Cytoplasmic proteins were precipi-
tated from the 100,000 
 
g
 
 supernatant using methanol/chloroform (Wessel
and Függe, 1984). All pellets were resuspended in SDS sample buffer,
boiled for 5 min, and stored at 
 
2
 
20
 
8
 
C. Protein concentration was deter-
mined using amido black staining of protein extracts on nitrocellulose fil-
ters (Schaffner and Weissmann, 1973). Equal amounts of protein were
separated on 16% polyacrylamide gels by SDS-gel electrophoresis (Laemmli,
1970) and transferred to nitrocellulose membranes (Immobilon P; Milli-
pore Corp., Milford, MA). Membranes were blocked overnight in TBST
(10 mM Tris, pH 8, 150 mM NaCl, 0.05% Tween 20) containing 1% BSA,
incubated with affinity purified anti-H-rev107 antibody (Hajnal et al., 1994)
diluted 1:1,000 in TBST for 4 h. Membranes were washed three times for 5
min in TBST and incubated for 45 min with an anti–rabbit horse-radish
peroxidase coupled antibody and processed according to the manufac-
turer’s instructions (ECL-Kit; Amersham Intl., Buckinghamshire, En-
gland).
 
Immunohistochemistry and Immunofluorescence
 
Indirect immunoperoxidase staining on frozen tissue sections was per-
formed using the Vectastain-kit (Vector Laboratories, Burlingame, CA)
according to the protocol of the manufacturer. In blocking experiments,
the H-rev107 antiserum was preabsorbed with 8 
 
m
 
g/ml of bacterially ex-
pressed H-rev107 protein prior to incubation with the sections. For immu-
nofluorescence analysis, cells were grown on glass coverslips coated with
polyornithine (100 
 
m
 
g/ml). After fixation in 3% paraformaldehyde in
phosphate-buffered saline for 20 min, cells were permeabilized using 0.5%
Triton X-100 in PBS for 2 min. Coverslips were incubated with the H-rev
107 antiserum, diluted 1:100 in PBS/1% BSA, washed in PBS, incubated
with a DTAF-conjugated goat anti–rabbit antibody (Dianova GmbH,
Hamburg, Germany), washed in PBS, mounted in 5% Mowiol and ana-
lyzed with a fluorescence microscope (Zeiss Inc., Oberkochen, Germany).
For nuclear staining, cells were incubated with 1 
 
m
 
g/ml Hoechst 33258 flu-
orescent dye together with the second antibody.
 
Results
 
Growth-inhibitory and Tumor-suppressing Activity of 
the H-rev107 Protein
 
REF52 cells which overexpress 
 
H-rev107
 
 (Hajnal et al.,
1994), are resistant to 
 
RAS
 
 transformation, and forced
overexpression of 
 
RAS
 
 blocks their growth and eventually
causes cell death (Hirakawa and Ruley, 1988). Interest-
ingly, the adenovirus E1A nuclear protein, which re-
presses the 
 
H-rev107
 
 gene, abolishes the resistance of
REF52 cells to 
 
RAS
 
 (Hajnal et al., 1994). These observa-
tions suggested that 
 
H-rev107
 
 is responsible for 
 
RAS
 
-
induced  growth arrest or cell death. To test the hypothesis
that overexpression of 
 
H-rev107
 
 is growth inhibitory for
 
RAS
 
-transformed cells but not for normal cells, we have
stably transfected different 
 
H-rev107
 
 cDNA expression
constructs into immortal, nontumorigenic 208F rat fibro-
blasts, into the 
 
HRAS
 
 transformed rat fibroblasts FE-8, or
into the EJ
 
-RAS
 
 transformed rat hepatoma cell line
ANR4. FE-8 cells do not express endogenous 
 
H-rev107
 
,
while ANR4 cells exhibit very low levels of endogenous
 
H-rev107
 
 mRNA (Fig. 1 
 
A
 
). The plasmid pCDNA107
 
1
 
 di-
rects moderate expression of the full-length 
 
H-rev107
 
cDNA. An antisense expression vector pCDNA107
 
2
 
, the
plasmid pCDNA107 
 
D
 
C expressing the truncated 
 
H-rev107
Figure 1. (A) H-rev107 mRNA expression in rat tumor cell lines.
H-rev107 expression is detected in the immortal rat pancreas
epithelial cell line AR4IP, in the immortal nontumorigenic rat
fibroblasts 208F and REF52, and in F9, a phenotypic revertant
cell line, derived from FE-8. No or low H-rev107 mRNA is present
in ANR4 (EJ-RAS transformed rat liver cell line), AR42J, CRI-D2,
CRI-D11(rat pancreatic tumor cell lines), KNRK (Ki-RAS trans-
formed rat kidney cell line), NRK 49E epitheloid rat kidney cell
line, NRK 52F fibroblastoid rat kidney cell line, and FE-8, HRAS
transformed derivative of 208F. High expression of H-rev107
mRNA is detected in DHD and WB2054 (rat colon carcinoma
cell lines). The 1-kb H-rev107 mRNA transcript, 18S, and 28S
rRNA used as size markers are indicated. (B) Western blot anal-
ysis of H-rev107 protein overexpression in stably transfected FE-8
cells. 100 mg of crude extract from hygromycin B-resistant clones
transfected either with pCDNA1071 (clones 32, 33, 38, 42, 44) or
pCDNA107 DC (clones 24–31) were separated by electrophoresis
through a 16% SDS-polyacrylamide gel, transferred to nitrocellu-
lose, and incubated with the H-rev107 polyclonal antiserum. The
full-length H-rev107 protein of z16 kd is detected only in clones
33 and 44; the truncated form of 14 kd is detected in clones 24–26
and 28–31. 10 ng of recombinant H-rev107 protein were loaded
together with the marker (M) giving a strong signal of 16 kd, re-
active with the H-rev107 antiserum. The same extracts were used
to investigate expression of the p21 HRAS gene product, shown
in the lower panel. All clones express the RAS protein except
clone 27.The Journal of Cell Biology, Volume 136, 1997 938
cDNA, and the plasmid pCDNA3 were used as controls.
The cloning efficiencies of FE-8 and ANR4 cells, following
the introduction of the plasmid pCDNA1071, were re-
duced by 62 and 75%, respectively, as compared to control
transfections (Table I).
After stable transfection of FE-8 cells with pCDNA1071,
only 5 of 13 isolated FE-8 clones showed significantly ele-
vated levels of the H-rev 107 protein, as determined by
Western blots. In contrast, eight out of nine clones trans-
fected with pCDNA107 DC expressed the truncated form
of the H-rev107 protein (Fig. 1 B). Immunofluorescence
analysis of the five independent pCDNA1071 transfec-
tant clones using the H-rev107 antiserum, revealed that
only 20–50% of the cells were positive for the protein.
Within a few weeks of culture, the fraction of H-rev107
positive cells decreased to ,10% (data not shown). A sig-
nificant reduction of colony formation was not observed in
transfections of nontumorigenic 208F cells excluding an
unspecific toxicity of H-rev107 expression plasmids (Table I).
These experiments showed that the level of H-rev107 ex-
pression inversely correlated with the clonogenicity of
HRAS-transformed cells transfected with the full-length
H-rev107 cDNA. Moreover, there was a strong selection
against H-rev107 expressing cells during continued culture
of transfectants.
To confirm this, we also transfected the pCMVTK1071
vector, which yields very high H-rev107 protein levels in
the transfected cells due to the presence of the thymidine
kinase leader sequence cloned in front of the H-rev107
cDNA. Transfection of this H-rev107 expression vector
did not yield individual stable ANR4 transfectant clones,
while only few colonies were formed after selection of FE-8
cells. None of 11 clones tested expressed H-rev107,
whereas HRAS protein expression was maintained, indi-
cating that a very high H-rev107 expression in the pres-
ence of HRAS does not permit permanent proliferation of
transfectants in vitro. In addition to the stably transfected
cells, FE-8 fibroblasts harboring the H-rev107 cDNA under
the control of a tetracycline-inducible promoter (pUHD-
107), were tested for their cloning efficiencies with or with-
out induction of the H-rev107 protein (Fig. 2). A reduction
in cloning efficiency similar to that observed with constitu-
tively expressed H-rev107 was obvious in cells with
pUHD-107 (Fig. 2). Upon prolonged culture of these cells
in the presence of doxycycline, there was again a selection
against H-rev107 expressing cells (data not shown).
To analyze the effects of H-rev107 overexpression on
proliferation in vivo, we generated FE-8 and ANR4 trans-
fectants with the same expression vectors as above. To
minimize loss of H-rev107 expressing cells due to pro-
longed culture in vitro, colonies resistant to the selective
agent were trypsinized, after they had reached a size of
more than 200 cells, and pooled. 8 d after trypsinization
and replating we performed immunofluorescence analysis
to determine the fraction of H-rev107 positive cells. A rep-
resentative culture of FE-8 transfectants is shown in Fig. 3
(A and C). To quantitate the H-rev107 positive fraction of
cells transfected with pCMVTK1071, we counted the cells
present in several independent microscopic fields of FE-8
and ANR4 transfectants. The proportion of H-rev107 pos-
itive cells was 56% in a total of 614 cells counted. FE-8 and
ANR4 cells transfected with the antisense expression vec-
tor, or transfected with a pCDNA3 plasmid directing the ex-
pression of an unrelated gene, formed progressively grow-
ing tumors after a latency period of 4–6 d. In transfected
FE-8 populations, the latency period increased only mar-
ginally, while it increased to 9–13 d in ANR4 populations
(Fig. 4). The tumors formed after injection of FE-8 and
ANR4 cell pools transfected with the high expressing plas-
Table I. Colony Formation of Cells Transfected with H-rev107 
Expression Vectors and Control Plasmids
Cell type Transfected cDNA
Number of colonies/
105 cells/mg plasmid DNA
Percentage of
colony growth
ANR4 pCDNA1071 1.18 6 0.35 25.7
ANR4 pCDNA1072 5.4 6 0.7 117.9
ANR4 pCDNA107 DC 2.76 6 0.42 60.3
ANR4 pCDNA3 4.58 6 0.52 100
FE-8 pCDNA1071 62.5 6 15.62 38.6
FE-8 pCDNA1072 193 6 24.33 119.1
FE-8 pCDNA107 DC 111.2 6 17.73 68.6
FE-8 pCNDA3 162 6 7.79 100
208F pCDNA1071 310 6 54.2 98.4
208F pCDNA1072 267.6 6 11.39 84.9
208F pCDNA107 DC 340 6 43.93 107.9
208F pCDNA3 315 6 30 100
106 cells were cotransfected with 1 mg pY3, 5 mg recombinant expression vector, and
20 mg of high molecular weight carrier DNA. Stable transfectants were selected in
medium containing hygromycin B. Resistant colonies were counted in triplicate cul-
tures, and numbers were normalized to the number of colonies obtained per mg DNA
in 105 transfected cells. Colony numbers obtained after transfection with the control
plasmid pCDNA3 were arbitrarily taken as 100% colony growth. H-rev107 expression
vectors were cloned as described in Materials and Methods. FE-8 cells (HRAS-trans-
formed rat 208F), ANR4 cells, (HRAS-transformed rat hepatocellular carcinoma), and
208F cells (nontransformed, immortalized rat fibroblasts).
Figure 2. Tet-inducible FE-8 transfectants. Colony formation of
FE-8 cells expressing H-rev107 (107-15) and control cells contain-
ing the vector only (10-3-3) after induction with doxycycline. 2000
cells/25 cm2 tissue culture flask were plated and grown either in
the presence (1) or on the absence (2) of 2 mg/ml doxycycline.
Medium containing fresh doxycycline was changed every three
days. Samples were analyzed in duplicates.Sers et al. Transformation-suppressing Activity of H-rev107 939
mid pCMVTK1071 enlarged more slowly than control
transfectants until about day 11. Afterwards, the differ-
ences in tumor sizes originating from cells transfected ei-
ther with full length H-rev107 cDNA or H-rev107 anti-
sense constructs gradually disappeared. No significant
differences in the size of tumors could be observed at 20 d
after injection. Cells transfected with the truncated H-rev107
cDNA (pCDNA107 DC) did not suppress tumor growth in
vivo (Fig. 4). After 14 or 20 d the mice were killed, and cells
from the tumors were explanted, grown in tissue culture,
and analyzed for H-rev107 protein by immunofluores-
cence. The proportion of transfected tumor cells positive
for H-rev107 protein was reduced as compared to the orig-
inal cells. A representative culture of tumor explants is
shown in Fig. 3 (B and D). Counting of independent mi-
croscopic fields of FE-8 transfectants (866 cells counted)
and ANR4 transfectants (784 cells counted) revealed an
average of 15% of cells staining positive with the H-rev107
antibody. These results suggest that either H-rev107 ex-
pression was downregulated in most of the cells during in
vivo passaging or that the H-rev107 expressing cells are effi-
ciently overgrown by the nonexpressing cells.
Intracellular Localization of the H-rev107 Protein
The product of the H-rev107 gene is an intracellular pro-
tein of 160 amino acids found either in the cytoplasmic or
in the membrane fractions of cell extracts. Density-depen-
dent growth arrest of 208F fibroblasts leads to an accumu-
lation of the protein in the membrane fraction (Hajnal et al.,
1994). To analyze the subcellular localization of this in
vitro, weakly expressed protein in more detail, H-rev107
was transiently overexpressed in COS cells or in 208F im-
mortal rat fibroblasts. Expression of the full-length protein
using the strongly expressing vector pCMVTK-1071 was
analyzed by Western blot technique, after biochemical
fractionation of cellular extracts, and by immunofluores-
cence staining and subsequent inspection by confocal laser
Figure 3. Loss of H-rev107 expression during tumor growth in vivo. H-rev107 expression in populations of FE-8 cells stably transfected
with pCMVTK1 cDNA. (A and B) Cells were incubated with the H-rev107 antiserum and stained with a DTAF-conjugated goat anti–
rabbit antibody. (C and D) Nuclei were stained with Hoechst 33258. (A and C) Transfected cells prior to injection into nude mice. (B
and D) Cell cultures explanted from tumor and grown in culture. Photographs of cells before injection and after explantation were
taken using the same exposure times. Bar, 20 mm.The Journal of Cell Biology, Volume 136, 1997 940
microscopy. Western blotting of nuclear, membrane, and
cytoplasmic extracts of cells overexpressing H-rev107 re-
vealed presence of the protein in all three fractions (Fig. 5
A). The cytoplasmic fraction shows a single protein band,
while an additional band with slightly lower electrophoretic
mobility is detected in the nuclear and the membrane frac-
tions, suggesting posttranslational modification of the protein.
A plasmid expressing a truncated H-rev107 cDNA
(pCDNA-107  DC), lacking the last 25 codons, was also
overexpressed in COS cells. The missing region encodes
predominantly hydrophobic amino acids and is probably
responsible for membrane association. Deletion of this hy-
drophobic region leads to a loss of the H-rev107 protein in
the nuclear and in the crude membrane fractions. The
shortened H-rev107 DC protein is entirely found in the cy-
toplasmic fraction (Fig. 5 A), suggesting that the COOH-
terminal hydrophobic domain mediates the binding of
H-rev107 to an intracellular membrane. In cells overex-
pressing full-length H-rev107, immunofluorescence analy-
sis revealed no staining within the nucleus and at the
plasma membrane. Rather, the H-rev107 protein appears
to be linked to the nuclear membrane and to membranes
in the perinuclear space (Fig. 5, B and C). As a consider-
able amount of the protein is present in the cytoplasm,
staining of the free protein presumably masks the exact lo-
calization of the membrane-bound polypeptide.
Expression of H-rev107 mRNA in Normal Adult Rat 
Tissues, Tumor Cell Lines, and Experimental Tumors
High levels of H-rev107 mRNA expression have been
observed in the RAS-transformation-resistant fibroblasts
REF 52 and EK3 and in the phenotypic revertant cell line
F9 obtained from HRAS-transformed cells. To further in-
vestigate the role of H-rev107 in neoplasia, we compared
the expression of the gene in various normal rat tissues
and tumor cell lines. Northern blot analysis of mRNA ob-
tained from adult rat tissue showed ubiquitous expression
of the H-rev107 gene (Fig. 6). Strong expression was ob-
served in brain, kidney, liver, stomach, large intestine,
spleen, muscle, and heart. A weaker expression was de-
tected in breast and small intestine, and a very weak signal
was observed in placenta. The H-rev107 protein is detect-
able in protein extracts from epithelial tissues of adult rats
(Hajnal et al., 1994). Immunohistochemistry on cryosec-
tions of normal rat tissues using the H-rev107 antibody
was used to localize H-rev107 expression in the tissues. In
the colon, strong H-rev107-specific staining was limited to
the differentiated epithelial cells. Similarly, epithelial spe-
cific expression was found in stomach, small intestine, and
esophagus, in tracheal and bronchial epithelium, in testis,
and in transitional epithelium of the bladder (Fig. 7).
Weaker expression was also observed in the cardiac mus-
cle and in spleen (data not shown).
In contrast to the normal tissues the rat liver carcinoma
cell line ANR4 expressed only low levels of H-rev107
mRNA. No mRNA was detectable in two immortal kid-
ney cell lines, NRK 49F and NRK 52E, or in the Ki-RAS
transformed kidney cell line KNRK. The highest expres-
sion levels were detected in the colon carcinoma cell lines
WB2054 and DHD (Fig. 1 A). The H-rev107 sequences
transcribed in these tumorigenic cell lines are presumably
wildtype, since analysis of RNAs prepared from WB 2054
and DHD cells by RT-PCR, SSCP, and sequencing of
PCR fragments did not provide evidence for mutations in
the coding sequences of H-rev107. However, analysis of
the H-rev107 protein expression using the H-rev107 anti-
body revealed very low levels in WB2054 and no detect-
able staining in DHD (data not shown). H-rev107 mRNA
was also expressed in the immortal, nontumorigenic pan-
creatic cell line AR4 IP and in normal human pancreas
(Husmann, K., C. Sers, and R. Schäfer, manuscript in
preparation). Very low levels were present in the two pan-
creatic carcinoma lines Cri-D11 and Cri-D2, and no H-rev-
107 mRNA could be detected in the tumorigenic pancreas
line AR4 2J (Fig. 1 A).
To find out if H-rev107 expression is altered in malig-
nant tissues, we analyzed tumors derived from transgenic
mice carrying an activated HRAS oncogene controlled by
the whey acidic protein promoter. The whey acidic protein
promoter is activated upon onset of lactation in the mam-
mary epithelial cells, leading to the development of mam-
mary tumors in certain transgenic lines (Andres et al.,
1987).  H-rev107 mRNA expression was absent or very low
in tumors L 25, 25.33G, and 25.72 (Fig. 8). Compared to
the two control samples (Fig. 8; normal-A, normal-B), also
the tumors 25.81, 25III13B, and 25.89 show a clear reduc-
tion in H-rev107 mRNA levels. Immunohistochemical
analysis of the same malignant tissues failed to detect ex-
pression of the H-rev107 protein in spite of detectable
mRNA. Western blot analysis of preneoplastic 208F rat fi-
broblasts and mouse NIH3T3 cells had shown a weak sig-
nal derived from the endogenous protein (Hajnal et al.,
Figure 4. Attenuation of tumor growth in nude mice mediated by
overexpression of H-rev107 cDNA in FE-8 and ANR4 cells. 106
cells from pools of FE-8 cells (s) and ANR 4 cells (d) stably
transfected with the following plasmids: 1, pCMVTK-1071
(sense); 2, pCMVTK107- (antisense); 3, pCNDA 107 DC (trun-
cated), were injected subcutaneously into either side of nude mice.
Latency period of individual tumors measured is the time until
tumor nodules were palpable.Sers et al. Transformation-suppressing Activity of H-rev107 941
1994 and Sers, C., unpublished observations), but detec-
tion of the protein in individual cells was not possible. This
is most likely due to a very low protein level, a phenome-
non also observed in the rat colon carcinoma line WB2054,
substantiating the notion that H-rev107 downregulation
can occur at the RNA and the protein level.
Discussion
Several lines of evidence suggest that H-rev107 is a trans-
formation-suppressing gene. We have previously reported
that H-rev107 mRNA is below the limit of detection in
HRAS transformed cells as shown by Northern blot analy-
sis, and that the gene was upregulated in the phenotypic
revertant cell line F9 and in two different HRAS-transfor-
mation-resistant fibroblast lines (Hajnal et al., 1994). In
this paper, we have shown that H-rev107 downregulation
is frequent in tumorigenic rodent cell lines and in murine
tumors, while the gene is ubiquitously expressed in the
corresponding normal tissues. Most importantly, transfec-
tion of H-rev107 cDNA expression vectors into two differ-
ent HRAS-oncogene expressing cell lines resulted in the
suppression of colony formation. Clones permanently
overexpressing the H-rev107 protein could not be ob-
tained. In vivo, ectopic expression of H-rev107 leads to the
attenuation of tumor growth in nude mice. Populations of
explanted tumor cells did not express significant amounts
of the H-rev107 protein.
What is the mechanism of growth suppression due to the
overexpression of the H-rev107 gene? Only a minor reduc-
tion of colony formation was observed in cells transfected
with the truncated H-rev107 gene (Table I). Expression of
the truncated gene can be maintained stably in culture and
did not result in a reduction of tumor growth (Fig. 1 B and
Fig. 4). This suggests that the membrane attachment of the
protein plays an important role in the proliferation–sup-
pressive function in vivo. The H-rev107 protein is clearly
not associated with the plasma membrane in 208F fibro-
blasts but rather with yet undefined intracellular mem-
Figure 5. (A) Subcellular localization of the full length H-rev107
protein in the nuclear (107-Nuc), the membrane (107-Mem), and
the cytoplasmic fractions (107-Cyt) of COS cells transiently trans-
fected with the pCMV-TK107 expression vector. The truncated
H-rev107 protein expressed after transfection with the plasmid
pCDNA107 DC is only detectable in the cytoplasmic fraction
(DC-Cyt) but absent from the nuclear (DC-Nuc) and the mem-
brane fractions (DC-Mem). For Western blot analysis, cells were
lysed 48 h after transfection and extracts fractionated as de-
scribed in Material and Methods. 20 mg of each fraction were
separated by electrophoresis through a 16% polyacrylamide gel,
blotted, and processed using the ECL method. Molecular size
markers in kd are indicated, H-rev107 proteins of z16 kd and the
truncated H-rev107 DC proteins of z14 kd are indicated. (B and
C) Immunofluorescence analysis by confocal laser microscopy of
ectopically expressed H-rev107 protein in 208F rat fibroblasts.
Cells transfected with the plasmid pCMVTK1071 were grown on
coverslips, fixed using 3% paraformadehyde and incubated with
the H-rev107 antiserum as described in Material and Methods.
Bar, 10 mm.
Figure 6. H-rev107 mRNA expression in various normal adult rat
tissues. 15 mg of glyoxal-denatured total RNA prepared from the
tissues indicated were separated by electrophoresis through a 1%
agarose gel, blotted, and hybridized using a 523-bp cDNA frag-
ment encoding part of the H-rev107 coding sequence. The 1-kb
H-rev107 mRNA transcript, 18S, and 28S rRNA used as size
markers are indicated.The Journal of Cell Biology, Volume 136, 1997 942Sers et al. Transformation-suppressing Activity of H-rev107 943
branes and presumably with the nuclear membrane. An
attractive speculation is that the H-rev107 protein may
serve as a negative regulator of an oncogenic HRAS-
mediated signal by sequestration of kinases or of other
growth-regulatory proteins. Members of the signal trans-
duction kinase cascade have been shown to bind to an-
choring proteins. These proteins target their catalytically
active partners to specific subcellular sites and thereby
control activation and phosphorylation of specific sub-
strates (Mochly-Rosen et al., 1991; Coghlan et al., 1995).
To understand the role of the H-rev107 protein in growth
suppression in molecular detail, it is important to identify
the target membrane and interacting proteins.
With constitutive expression of oncogenic RAS, slow
growing cell populations overexpressing the H-rev107 gene
are easily taken over by the fast-growing, nonexpressing
cell populations. Thus, a detailed analysis of growth arrest
in specific stages of the cell cycle was hampered by such an
instability of H-rev107 high-expressers among RAS-trans-
formants and by the low concentrations of the endogenous
H-rev107 protein in cultured cells. The endogenous H-rev107
protein was detected exclusively in differentiated epithe-
lial cells of several tissues, suggesting that it plays a role in
differentiation-related growth arrest. We did not observe a
significant fraction of apoptotic cells in transfected cell
cultures (data not shown). Thus, the reduction of colony
formation of transfected HRAS-transformed cells and the
replacement of H-rev107-expressing cells by negative cells
in vivo and in vitro may be explained by induced senes-
cence, which is regarded as an important mechanism of tu-
mor suppression (O’Brien et al., 1986; Shay and Wright,
1991).
The H-rev107 gene can be categorized as a class II tu-
mor suppressor gene which has lost a growth-constraining
function in tumor cells due to an expression block (Lee et al.,
1991). In class I tumor suppressor genes such as TP53 or
RB (for review see Vogelstein and Kinzler, 1992; Riley et al.,
1994), loss of function results from mutation or deletion of
DNA. Furthermore, the concept of two classes of tumor
suppressor genes suggests that some class II genes are the
targets of class I genes encoding transcriptional regulators
(Lee et al., 1991). An increasing number of class II tumor
suppressor genes have been identified on the basis of their
downregulation in tumorigenic cells and owing to their
transformation-inhibiting activity. The product of the
K-rev gene, a Ras-like GTP-binding protein, was shown to
interfere with oncogenic signaling (Kitayama et al., 1989;
Frech et al., 1990; Culine et al., 1992). Other class II genes
encode the cytoskeletal proteins tropomyosin (Fernandez
et al., 1992) and vinculin (Prasad et al., 1993), the matrix-
modifying enzyme lysyl oxidase (Contente et al., 1990;
Krzyzoziak et al., 1992; Hajnal et al., 1993), gap junction
proteins (Lee et al., 1992), and the invasion modulating
serine protease maspin (Zou et al., 1994).
We have observed a concerted expression block to sev-
eral H-rev genes in HRAS-transformed cells. Downregula-
tion affected the H-rev107 gene (Hajnal et al., 1994), the
H-rev142 gene encoding lysyl oxidase (Hajnal et al., 1993;
Oberhuber et al., 1995), the H-rev18 gene encoding Ril, a
novel member of LIM double zinc finger proteins involved
in differentiation (Kiess et al., 1995), and Tsp-1 encoding
the angiogenesis inhibitor thrombospondin (Shäfer, R.,
unpublished observations). These findings support the no-
tion that continuous mitogenic signaling by mutated RAS
specifically results in the coordinated downregulation of
critical genes.
The repression of class II suppressor gene activity medi-
ated by onco-proteins provides an important novel link
between the activity of oncogenes and anti-oncogenes.
The most intriguing feature of class II tumor suppressor
inactivation is perhaps its reversibility triggered by various
agents (Contente et al., 1990; Krzyzosiak et al., 1992;
Oberhuber et al., 1995). Upregulation of H-rev gene ex-
pression in phenotypic revertants may occur in a coordi-
nated fashion (Hajnal et al., 1993; Oberhuber et al., 1995).
Several drugs have been identified that are able to rees-
tablish the expression of downregulated genes and revert
the transformed phenotype (Krzyzosiak et al., 1992; Kumar
et al., 1995). The further development of those drugs may
provide new therapeutic options for interfering with the
activity of oncogenes commonly activated in human neoplasia.
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Figure 7. Immunohistochemical detection of the H-rev107 protein in the terminally differentiated epithelial cells of (A) stomach, (C)
colon, (E) kidney, and (G) bladder. Analysis on cryostat sections of normal adult rat tissues was performed as described in Materials
and Methods. The same tissues were stained after preabsorption of the antiserum with 8 mg/ml purified H-rev107 protein, showing no
unspecific reactivity in (B) stomach, (D) colon, (F) kidney, and (H) bladder. Bars: (B–H) 50 mm; (A, C, and D) 100 mm.
Figure 8. H-rev107 mRNA expression in the normal mammary
gland and loss of H-rev107 mRNA in a subset of mammary tu-
mors of whey acidic protein-RAS transgenic mice. Numbers refer
to individual tumors. The 1-kb H-rev107 mRNA transcript, 18S,
and 28S rRNA as size markers are indicated.The Journal of Cell Biology, Volume 136, 1997 944
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